ScholarIQanswers from OpenAlex

Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations

PaperCitations, authors & open-access status

Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations have?

ScholarIQcitation count

Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations has 4 citations in the OpenAlex counts ScholarIQ stores.

When was Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations published?

ScholarIQyear

Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations has 2025 year in the ScholarIQ index.

What is the open-access status of Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations?

ScholarIQoa status

Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations has closed oa status in the ScholarIQ index.

What is the DOI of Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations?

ScholarIQdoi

The DOI for Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations is on the source record.

What is the PMID of Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations?

ScholarIQpmid

The PMID for Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations is on the source record.

What is the OpenAlex record for Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations?

ScholarIQopenalex

The OpenAlex for Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial